⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851902 | 0.69 | — | — | |
| SCHEMBL6534653 | 0.67 | — | — | |
| SCHEMBL37921 | 0.67 | — | — | |
| Allylamine SCHEMBL995919 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL5838863 | 0.64 | — | — | |
| SCHEMBL9738638 | 0.64 | — | — | |
| Bromide SCHEMBL8432007 | 0.64 | ALDH1A1 (0.36) | — | |
| SCHEMBL1122022 | 0.64 | — | — | |
| Water SCHEMBL11593864 | 0.64 | — | — | |
| SCHEMBL6464083 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| EP-2291359-A1 | PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | claimed |
| US-20100080786-A1 | Phenyl or Pyridinyl Substituted Indazoles Derivatives | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | claimed |
| WO-2009142569-A1 | PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | claimed |
| EP-3140301-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | Orion Corporation (FI) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015169999-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2015-11-12 | — | — | WO | disclosed |
| EP-2291359-A1 | PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20100080786-A1 | Phenyl or Pyridinyl Substituted Indazoles Derivatives | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
| WO-2009142569-A1 | PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009009613-A2 | NOVEL ION CHANNEL-FORMING PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-01-15 | — | — | WO | disclosed |